If security is the immune system in our application that identifies and neutralises threats, often before you notice them, then compliance is the memory and intelligence that guides it—knowing what to look for, how to respond, and when to escalate. Together, they protect the whole system.

White paper: randomisation methods. Pros, cons, and reflections from Spiral Software CEO, Audrey Shearer.

The GKPTN registry and the CAPTIVATE trial could find new treatments for people with kidney disease and change how trials are conducted in patients with kidney disease.

I can boldly say that Spiral is a global leader in novel clinical trial innovation and, more specifically, in randomisation. We’re redefining the parameters of randomisation in all its forms and building a future-ready platform with Blazor’s next-gen development framework - Audrey.

This circuit presents a critical opportunity for collaboration with researchers leading and advancing infectious disease research. A primary message for us all; ‘Engage Early.’

Spiral spent an inspirational and thought-provoking weekend at the 2024 ASID Clinical Research Meeting on the Gold Coast. Read the latest insights and takeaways from our founder and CEO, Audrey Shearer.

Spiral is proud to have played a crucial role in the success of the PANORAMIC clinical trial, which, along with the PRINCIPLE trial, has recently been awarded the prestigious Prix Galien Best Public Sector Innovation Award 2024. 

Spiral is navigating the intersection of big data and AI —leading the way in ethical clinical trial design. In the rapidly evolving healthcare landscape, we prioritise ethical governance, where data, compliance, and human-centred trials converge.

In the fast-paced world of software, adaptability is key. Our Spinnaker software is always evolving to stay innovative. Because of this, we're now rebuilding a project from the ground up, seizing the chance to harness Blazor, a cutting-edge web development framework, as we navigate changes in the Core Protocol.